• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Financial Officer Bauerlein Alison sold $78,927 worth of shares (19,260 units at $4.10), decreasing direct ownership by 3% to 617,468 units (SEC Form 4)

    7/7/25 9:27:26 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care
    Get the next $SGHT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Bauerlein Alison

    (Last) (First) (Middle)
    C/O SIGHT SCIENCES, INC.
    4040 CAMPBELL AVE., SUITE 100

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Sight Sciences, Inc. [ SGHT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    07/02/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 07/02/2025 S 19,260(1) D $4.098 617,468 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units.
    /s/ Jeremy Hayden, Attorney-in-Fact for Alison Bauerlein 07/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SGHT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SGHT

    DatePrice TargetRatingAnalyst
    8/8/2025$5.00Hold → Buy
    Lake Street
    12/6/2024$5.50Buy
    UBS
    11/4/2024$10.00 → $5.00Buy → Hold
    Lake Street
    8/21/2024$10.00Buy
    Lake Street
    9/12/2023$10.00 → $4.50Neutral → Underperform
    BofA Securities
    9/12/2023$15.00 → $5.50Overweight → Neutral
    Piper Sandler
    9/12/2023Outperform → Mkt Perform
    William Blair
    8/24/2023$12.00 → $8.40Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SGHT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sight Sciences upgraded by Lake Street with a new price target

    Lake Street upgraded Sight Sciences from Hold to Buy and set a new price target of $5.00

    8/8/25 8:25:35 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    UBS initiated coverage on Sight Sciences with a new price target

    UBS initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $5.50

    12/6/24 8:14:13 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences downgraded by Lake Street with a new price target

    Lake Street downgraded Sight Sciences from Buy to Hold and set a new price target of $5.00 from $10.00 previously

    11/4/24 8:26:06 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

    MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the second quarter ended June 30, 2025, and raised its revenue guidance while reaffirming its adjusted operating expense guidance, both for full year 2025. Recent Financial and Business Highlights Generated second quarter 2025 total revenue of $19.6 million, a decrease of 8% compared to the same period in the prior year. This expected decline was primarily due to low

    8/7/25 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

    MENLO PARK, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced the results of a cost-utility analysis (CUA) assessing the cost-effectiveness of the TearCare® System compared to cyclosporine 0.05% (CsA) for the treatment of moderate to severe meibomian gland disease (MGD) associated dry eye disease (DED). The analysis, published ahead of print in Expert Review of Pharmacoeconomics and Outcomes Research, demonstrated that TearCare is not only associated with greater heal

    7/30/25 7:00:00 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

    MENLO PARK, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced that the manuscript detailing 24-month results from Stage 3 of the SAHARA randomized controlled trial (RCT) has been published ahead of print (PAP) by Optometry and Vision Science (Official Journal of the American Academy of Optometry) and is available online in pre-publication format. All mean signs and symptoms remained statistically significantly better than the study baseline at all time points measured

    7/29/25 7:00:00 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Encrantz Staffan bought $381,958 worth of shares (90,525 units at $4.22) and was granted 30,952 shares, increasing direct ownership by 10% to 1,377,964 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    6/6/25 9:10:58 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Director Encrantz Staffan bought $376,429 worth of shares (98,782 units at $3.81), increasing direct ownership by 9% to 1,256,487 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    6/3/25 9:57:16 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Director Encrantz Staffan bought $451,734 worth of shares (128,189 units at $3.52), increasing direct ownership by 12% to 1,157,705 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    5/29/25 9:31:17 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    SEC Filings

    View All

    SEC Form 10-Q filed by Sight Sciences Inc.

    10-Q - Sight Sciences, Inc. (0001531177) (Filer)

    8/7/25 4:19:50 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sight Sciences, Inc. (0001531177) (Filer)

    8/7/25 4:09:30 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Sight Sciences Inc.

    8-K - Sight Sciences, Inc. (0001531177) (Filer)

    6/5/25 4:46:57 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Badawi David exercised 40,000 shares at a strike of $0.12, increasing direct ownership by 2% to 1,871,025 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    7/18/25 6:36:35 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Chief Legal Officer Hayden Jeremy B. sold $38,234 worth of shares (9,160 units at $4.17), decreasing direct ownership by 3% to 266,321 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    7/7/25 9:32:01 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    President and CEO Badawi Paul sold $98,141 worth of shares (23,637 units at $4.15), decreasing direct ownership by 0.39% to 5,986,943 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    7/7/25 9:27:20 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    Financials

    Live finance-specific insights

    View All

    Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

    MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the second quarter ended June 30, 2025, and raised its revenue guidance while reaffirming its adjusted operating expense guidance, both for full year 2025. Recent Financial and Business Highlights Generated second quarter 2025 total revenue of $19.6 million, a decrease of 8% compared to the same period in the prior year. This expected decline was primarily due to low

    8/7/25 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

    MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the second quarter ended June 30, 2025, after the market close on Thursday, August 7, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightscienc

    7/24/25 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

    MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025.   Recent Financial and Business Highlights Generated first quarter 2025 total revenue of $17.5 million, a decrease of 9% compared to the same period in the prior year. This decline was primarily due to lower revenue from the Company's

    5/8/25 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sight Sciences Inc.

    SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

    11/14/24 11:57:36 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Sight Sciences Inc. (Amendment)

    SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

    2/14/24 5:24:02 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Sight Sciences Inc.

    SC 13G - Sight Sciences, Inc. (0001531177) (Subject)

    2/13/24 6:52:37 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    Leadership Updates

    Live Leadership Updates

    View All

    Sight Sciences Appoints Gary Burbach to its Board of Directors

    MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. "We are very excited to add Gary to our Board of Directors," stated Paul Badawi, Co-founder and Chief Executive Officer of Sight Sciences. "He brings a strong medtech industry background with a pro

    4/22/25 4:05:00 PM ET
    $BWXT
    $SGHT
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

    MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con

    11/7/24 4:04:00 PM ET
    $INGN
    $SGHT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    Sight Sciences Appoints Matt Link as Chief Commercial Officer

    MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced the appointment of Matthew Link as its Chief Commercial Officer, effective September 11, 2023. "We are very excited to have Matt join Sight Sciences as we scale our Surgical Glaucoma and Dry Eye businesses. Matt is a highly talented medtech business leader with a track record of success in transforming treatment paradigms with disruptive new technology, and predictably scaling in a public high-growth

    9/11/23 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care